News | July 28, 2022
Dr Lal Path Labs Q1 FY23 consolidated PAT drops to Rs. 57.7 Cr
Dr. Lal Path Labs has reported total income of Rs. 511 crores during the period ended June 30, 2022
Dr. Lal Path Labs has reported total income of Rs. 511 crores during the period ended June 30, 2022
Aarti Drugs Limited has reported total income of Rs. 622.22 crores during the quarter ended June 30, 2022.
The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 94.30 crores during the period ended June 30, 2022.
GlaxoSmithKline Pharmaceuticals has reported total income of Rs. 772.71 crores during the period ended June 30, 2022
Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022
Medidata Detect and Rave CTMS Have Improved Study Execution Through Role-Based Monitoring Workflows and Clinical Data Visualization for Hundreds of Customers Across More Than 9,000 Studies
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Subscribe To Our Newsletter & Stay Updated
